[{"address1": "2265 Upper Middle Road East", "address2": "Suite 602", "city": "Oakville", "state": "ON", "zip": "L6H 0G5", "country": "Canada", "phone": "289-910-0850", "fax": "905-481-2394", "website": "https://www.cardiolrx.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.", "maxAge": 86400, "priceHint": 4, "previousClose": 1.89, "open": 1.88, "dayLow": 1.79, "dayHigh": 1.89, "regularMarketPreviousClose": 1.89, "regularMarketOpen": 1.88, "regularMarketDayLow": 1.79, "regularMarketDayHigh": 1.89, "beta": 0.633, "forwardPE": -6.3793106, "volume": 306158, "regularMarketVolume": 306158, "averageVolume": 495033, "averageVolume10days": 1159310, "averageDailyVolume10Day": 1159310, "bid": 1.83, "ask": 1.86, "bidSize": 400, "askSize": 200, "marketCap": 127646864, "fiftyTwoWeekLow": 0.661, "fiftyTwoWeekHigh": 3.12, "fiftyDayAverage": 2.1661, "twoHundredDayAverage": 1.380985, "currency": "USD", "enterpriseValue": 99241040, "floatShares": 65827151, "sharesOutstanding": 68998304, "sharesShort": 266475, "sharesShortPriorMonth": 275235, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0039, "heldPercentInsiders": 0.04596, "heldPercentInstitutions": 0.12991999, "shortRatio": 0.79, "shortPercentOfFloat": 0.004, "impliedSharesOutstanding": 73381696, "bookValue": 0.294, "priceToBook": 6.292517, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -30218588, "trailingEps": -0.34, "forwardEps": -0.29, "enterpriseToEbitda": -3.284, "52WeekChange": 1.2839506, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CRDL", "underlyingSymbol": "CRDL", "shortName": "Cardiol Therapeutics Inc.", "longName": "Cardiol Therapeutics Inc.", "firstTradeDateEpochUtc": 1547562600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ee9d962b-eed4-3063-8df9-c815990fe5d8", "messageBoardId": "finmb_424954803", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.85, "targetHighPrice": 9.0, "targetLowPrice": 8.0, "targetMeanPrice": 8.5, "targetMedianPrice": 8.5, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 28572976, "totalCashPerShare": 0.414, "ebitda": -30222164, "totalDebt": 167136, "quickRatio": 2.646, "currentRatio": 2.807, "debtToEquity": 0.833, "returnOnAssets": -0.45347, "returnOnEquity": -0.92109, "freeCashflow": -9735083, "operatingCashflow": -22156452, "financialCurrency": "CAD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]